Scholars Central

Conference abstractPublished 13 Dec 2022

Circadian rhythm-related miR-6883-5p suppresses Enzalutamide-resistant prostate cancer proliferation via inhibiting AR-V7 expression

Authors: Wenchang Yue, Ying Xu, Jianquan Hou

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Prostate cancer is the second most prevalent cancer in men and the sixth leading cause of cancer death worldwide. Age, family history, race, tobacco use, obesity, diet, and circadian disruption are all risk factors for prostate cancer. Epidemiological studies of circadian disruption focus primarily on night shift work. The 2017 Nobel Prize in Physiology or Medicine was awarded to Jeffrey C. Hall, Michael Rosbash, and Michael W. Young for making it possible to study the molecular mechanisms underlying circadian rhythms. The molecular mechanisms between circadian rhythm genes and diseases, including prostate cancer, have been gradually revealed, and these studies hold promise for future clinical application. However, the relationship between the molecular mechanism of circadian rhythm and the development of prostate cancer has not been fully clarified. We observed that a microRNA plays an important role in the regulation of circadian rhythms and prostate cancer proliferation. Our study shows that miR-6883-5p is associated with circadian rhythm and can inhibit AR-V7, thereby suppressing the growth of enzalutamide-resistant prostate cancer. Our research provides a potential therapeutic target for enzalutamide-resistant prostate cancer and expands the understanding of circadian clock regulation regulatory mechanisms. Recent Publications 1. Yue W, Du X, Wang X, et al. Prognostic values of the core components of the mammalian circadian clock in prostate cancer. PeerJ. 2021;9:e12539. Published 2021 Dec 9. doi:10.7717/peerj.12539 2. Sun J, Yue W, You J, et al. Identification of a Novel Ferroptosis-Related Gene Prognostic Signature in Bladder Cancer. Front Oncol. 2021;11:730716. Published 2021 Sep 7. doi:10.3389/fonc.2021.730716 3. Sun J, Wei X, You J, et al. STC1 is a Novel Biomarker Associated with Immune Characteristics and Prognosis of Bladder Cancer. Int J Gen Med. 2021;14:5505-5516. Published 2021 Sep 11. doi:10.2147/IJGM.S329723 4. Yue W, et al. Circadian rhythm-related miR-6883-5p suppresses enzalutamide-resistant prostate cancer proliferation via inhibiting ARV7 expression. ( Contributing) 5. Yue W, et al. Important hub-RNAs in the development of prostate cancer identified by RIC-seq.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Clinical Nephrology and Research.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalClinical Nephrology and Research
  • SubjectNephrology & Urology
  • BylineArticles whose byline prints “Wenchang Yue”
  • BylineArticles whose byline prints “Ying Xu”
  • BylineArticles whose byline prints “Jianquan Hou”